Fractyl Health, Inc. (NASDAQ:GUTS) CEO Sells $238,396.99 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 96,517 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $1,213,582.63. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Fractyl Health Stock Down 2.5 %

Shares of GUTS traded down $0.06 during mid-day trading on Wednesday, hitting $2.37. The company’s stock had a trading volume of 375,016 shares, compared to its average volume of 318,194. The company’s 50-day moving average is $2.63 and its 200-day moving average is $4.05. Fractyl Health, Inc. has a 52-week low of $1.74 and a 52-week high of $14.50. The firm has a market capitalization of $113.59 million and a price-to-earnings ratio of -0.19. The company has a current ratio of 7.46, a quick ratio of 7.46 and a debt-to-equity ratio of 0.40.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. The business had revenue of $0.01 million during the quarter. On average, equities research analysts forecast that Fractyl Health, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds have recently modified their holdings of GUTS. Rhumbline Advisers purchased a new stake in shares of Fractyl Health in the 2nd quarter worth approximately $32,000. SG Americas Securities LLC purchased a new stake in Fractyl Health during the third quarter valued at approximately $33,000. Beta Wealth Group Inc. purchased a new stake in Fractyl Health during the third quarter valued at approximately $44,000. BNP Paribas Financial Markets lifted its position in Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after acquiring an additional 7,397 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Fractyl Health during the second quarter valued at approximately $61,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.